These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31076479)

  • 1. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
    Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
    Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
    Shih AH; Meydan C; Shank K; Garrett-Bakelman FE; Ward PS; Intlekofer AM; Nazir A; Stein EM; Knapp K; Glass J; Travins J; Straley K; Gliser C; Mason CE; Yen K; Thompson CB; Melnick A; Levine RL
    Cancer Discov; 2017 May; 7(5):494-505. PubMed ID: 28193779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
    Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
    Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
    Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
    J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
    Boila LD; Sengupta A
    Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
    Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
    Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
    Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
    Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
    Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
    Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
    Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
    Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
    Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
    Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
    Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
    Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone demethylase LSD1-mediated repression of GATA-2 is critical for erythroid differentiation.
    Guo Y; Fu X; Jin Y; Sun J; Liu Y; Huo B; Li X; Hu X
    Drug Des Devel Ther; 2015; 9():3153-62. PubMed ID: 26124638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
    Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
    Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
    Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
    Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.